11/10/2018 22:25:37

AMPIO PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Ampio Pharmaceuti

Lead Plaintiff Deadline is October 24, 2018     

NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. (“Ampio” or the Company”) (NYSE:  AMPE) in the United States District Court for the District of Colorado, on behalf of a class consisting of all persons who purchased or otherwise acquired the publicly traded securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the “Class Period”).

Investors who have incurred losses in the shares of Ampio Pharmaceuticals, Inc.

a

re urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of Ampio Pharmaceuticals, Inc., you may, no later than October 24, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Ampio Pharmaceuticals, Inc.   

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, Defendants failed  to disclose  that: 

  • the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled;

     

  • as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; 

     

  • consequently, Defendants’ public statements were materially false and misleading at all relevant times.

On August 7, 2018, after the market closed, Ampio announced updated business disclosures relating to its AP-003-A and AP-003-C trials, disclosing that the U.S. Food and Drug Administration (“FDA”) found that a single trial the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support a Biologics License Application (“BLA”) and that the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial.

On this news, shares of Ampio fell $2.25 per share or over 78% to close at $0.61 per share on August 8, 2018.

Wolf Haldenstein Adler Freeman & Herz LLP

 has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP

Kevin Cooper, Esq.

Gregory Stone, Director of Case and Financial Analysis

Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com

Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome. 

wolf_logo_color_tagline.jpg

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
16 Oct
DANSKE
Jeg tror aldrig jeg har oplevet en person, der var så bitter som du er. Du bruger en ufattelig masse..
34
19 Oct
DANSKE
Borgen og Andersen sad i direktionsvognen, på vej hjem efter en lang dag hos bagmandspolitiet. Stemn..
33
21 Oct
BAVA
J&J og Bavarian Nordic er ikke så offentlige omkring deres resultater med deres ebola-vaccine. Senes..
23
20 Oct
I:DAX
Matthew jeg har for sjov kigget lidt på resultaterne af dine kriterier for dødskryds. Det var mening..
20
18 Oct
I:DAX
Tjekkiets præsident Vaclav Klaus har et godt bud...   Europa er blevet svækket af den venstreoriente..
17
19 Oct
VWS
Vestas wins 294 MW order in South African auction and introduces the first V136-4.2 MW turbines in A..
15
17 Oct
VELO
  Virker også fint her. Vil desuden lige sende en stor ros til alle jer debattør, for en god og sagl..
15
22 Oct
 
Post nord deler stadig kinesiske pakker ud til latterlige 6,5 kr i porto mens alle andre betaler kas..
14
20 Oct
DANSKE
Fik uddelt en rigtig god solid kindhest til Danske bank, i forbindelse med at man fandt den unge And..
14
16 Oct
VELO
HVAD SIGER VELOXIS og HVAD GØR MARKEDET...    Lad os starte med hvad sagde Craig Collard ved regnska..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
2
VINCI : Eurovia wins two contracts to develop major corridors in North Carolina (United States)
3
NICE publishes advice on gammaCore for the treatment of cluster headache
4
BOURBON SUBSEA SERVICES wins a turnkey contract for the installation of the 25 MW Windfloat Atlantic floating offshore windfarm
5
Nano Dimension Continues Expansion in North America, Adds GoEngineer to US Reseller Channel

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2018 04:48:24
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181022.1 - EUROWEB6 - 2018-10-23 05:48:24 - 2018-10-23 04:48:24 - 1000 - Website: OKAY